Diabetes occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin. Symptoms associated with diabetes are frequent urination, blurred vision, increased thirst, rapid weight loss, numbness or tingling sensation in hands or feet and increased hunger. Factors which increase the risk of diabetes are ethnicity, family history, unhealthy diet, physical inactivity and smoking.Diabetes can damage the heart, eyes, blood vessels, kidneys, and nerves which may lead to disability and premature death. There are three types of diabetes, namely,type 1, type 2 and gestational diabetes. Type 1 diabetes can cause due to complex interaction between genes and environmental factors. The most common risk factors for type 2 diabetes are overweight and obesity. However, gestational diabetes develops only during pregnancy.
Continuous blood glucose monitoring devices continuously monitors the blood sugar level and displays the data on the monitor. Flash glucose monitors are also used to monitor blood glucose. The monitor shows reading only after scanning its sensor. The insulin pump is a computerized device that helps in controlling diabetes. This pump releases insulin through a catheter into the body. The user can adjust the dose of insulin to be delivered by this pump.
Antidiabetic drugs are used for controlling diabetes. These medicines help to control and stabilize the blood glucose level. In patients with type 1 diabetes, insulin is used,whereas in patients with type 2 diabetes, sulfonylureas, biguanides, meglitinides, dipeptidyl-peptidase-4 (DPP-4) inhibitors,alpha-glucosidase inhibitors, sodium glucose cotransporter 2 inhibitors (SGLT2), and glucagon-like peptide-1 (GLP-1) agonist are used. In type 1 diabetes, the insulin used is created by growing insulin proteins within E-coli bacteria in laboratory. The analog insulin is available into various forms. One of the forms is long acting analog insulin. The long acting analog insulin stays in the body for 24 hours,whereas the intermediate acting analog insulin stays in the body for 16 to 24 hours. Another form of insulin is rapid acting analog insulin. Rapid acting insulin stays the body for 3 to 5 hours. On the other hand, short acting analog stays in the body for 6 to 8 hours. Further, premixed analog insulin is also a form of insulin which is used in diabetes. It is made by combining rapid acting and long acting insulin in a ratio. However, in type 2 diabetes patients, sulfonylureas are used. Sulfonylureas stimulate the insulin production in the pancreas. Moreover, sulfonylureas help in increasing the amount of insulin which is produced by the pancreas. Thiazolidinedione’s is another class of antidiabetic drugs. Thiazolidinedione’s reduce insulin resistance in fat and muscles. They also lower glucose production by the liver.Meglitinide is another class of antidiabetic drug. Amount of insulin produced by pancreas is increased with the help of meglitinides. Moreover, GLP-I agonists help in maintenance of blood sugar in a target range without leading to low blood sugar or weight gain, whereas alpha glucosidaseinhibitors slow down the digestion of starch thus maintaining the blood sugar level.
The major driver for this market is increasing prevalence of diabetes.According to International Diabetes Federation, in 2015, diabetes affected 415 million people worldwide and this number is expected to reach up to 642 million by 2040. Thus, this rapidly rising diabetic population is set to drive the demand for diabetic devices and drugs market. Additionally, increase in prevalence of obesity in geriatric population is set to further drive the market growth.For instance, as per WHO, in 2014, more than 1.9 billion adults, 18 years and older,were overweight. Out of these, over 600 million were obese.Moreover, it states that, in 2014, 41 million children whose age was under 5 were obese or overweight. Further, increasing trend of unhealthy diet will contribute to the growth of diabetes devices and drugs market. However,regulatory framework issues will hamper the growth of diabetic devices and drug market.
The major strategy adopted by the major players is product launch to gain market share and to gain competitive edge. For instance, in 2015, Janssen India launched INVOKANA for diabetic patients. INVOKANAis a sodium glucose co-transporter 2 inhibitor. It helpsadults to achieve adequate control on diabeteswho previously were not able to achieve control on diabetes.
Some of the major players in the global diabetes devices and drugs market are GlaxoSmithKline PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, AstraZeneca, Johnson & Johnson Services, Inc., F. Hoffmann La-Roche Ltd., B. Braun Melsungen AG, Bayer AG, Becton, Dickinson and Company, BoehringerIngelheim International GmbH, DexCom, Inc., Eli Lilly and Company, Lupin Limited, Novo Nordisk A/S, Medtronic, Inc., Merck & Co., Inc., Novartis AG and Sanofi.
Diabetes Devices and Drugs Market Segmentation:
- Insulin Injectors
- Insulin Syringes
- Insulin Pumps
- Insulin Pens
- Diabetes Monitoring and Diagnostic Devices
- Continuous Glucose Monitoring Devices
- Analog Glucose Meter
- Lancets and Lancing Devices
- Glucose Test Strips
- Non-insulin Injectable Anti-diabetes Drugs
- Oral Anti-diabetes Drugs Class
- SGLT-2 Inhibitors
- DPP-4 Inhibitors
- Premixed Insulin Derivatives
- Intermediate-acting Insulin Derivatives
- Rapid-acting Insulin Derivatives
- Short-acting Insulin Derivatives
- Long-acting Insulin Derivatives
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- South Africa
- Saudi Arabia
- United Arab Emirates
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
Data Collection Matrix
Primary Data Sources
- Distributors & Wholesalers
- Healthcare Providers
Secondary Data Sources
- Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
- Government/Associations Publications
- Case Studies
- Reference Customers
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Quantitative Data (2017-2025)
- Market Dynamics (Drivers, Restraints, and Challenges)
- Industry Trend Analysis
- Market Opportunities
- Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
- Porter’s Five Forces and PESTLE Analysis
- Key Developments and Competitive Landscape
- Market Assessment and Forecast
- Market Assessment and Forecast, By Product
- Market Assessment and Forecast, By Technology
- Market Assessment and Forecast, By Application
- Market Assessment and Forecast, By End User
- Market Assessment and Forecast, By Region/Country